Dr. Jiménez has a PhD in Biomedicine from the University of Barcelona and studies in technology transfer in life sciences from the Barcelona School of Management – UPF, EADA business school and IESE. Moreover, she has led the formation of AtG Therapeutics as well as the critical step of transferring technology. She has closed the seed round for AtG. Dr. Jiménez defines the strategic and operational corporate planning of AtG Therapeutics.

Dr. Oriol Casanovas is an internationally acclaimed biomedical researcher with extensive expertise in basic and translational research involving murine cancer models and tumor angiogenesis. His groundbreaking work focuses on unravelling the implications of cancer treatment adaptation and resistance. Dr. Casanovas' scientific achievements have garnered significant recognition, with his findings published in esteemed cancer research journals.

Mr. Huisken is a seasoned entrepreneur, CEO, consultant, and NED (Non-Executive Director) with over 25 years of experience in business creation and management. Holding an MBA from INSEAD, Bart brings extensive expertise in Strategy, Corporate Innovation, Intrapreneurship, Lean Startup, Customer Discovery, B2B Sales, Employee Engagement, Trust, Fair Process, and Corporate Governance.

Dr. Canamasas is a highly experienced pharmaceutical executive with a PhD in Tumor Genetics from the University of Mainz and studies at Harvard Business School & IMD Business School. She is the former Head of Oncology EMEA at Bayer. She has 20+ years of experience in various senior oncology leadership positions with expertise in global commercialization, life-cycle development, corporate strategy, organizational development & country leadership.